石四药集团(02005)已取得国家药监局有关安瓿包装的碳酸氢钠注射液的药品生产注册批件

智通财经
31 Mar

智通财经APP讯,石四药集团(02005)发布公告,本集团已取得中国国家药品监督管理局(国家药监局)有关安瓿包装的盐酸尼卡地平注射液 (10ml: 10mg)的药品生产注册批件,属于化学药品第4类,视同通过一致性评价。安瓿包装的盐酸尼卡地平注射液主要用于手术时异常高血压的紧急处理及高血压急症。诚如本公司日期为2025年3月5日的公告所载,本集团的盐酸尼卡地平原料药已获国家药监局批准登记成为在上市制剂使用的原料药。

董事局亦欣然公告,本集团已取得国家药监局有关安瓿包装的碳酸氢钠注射液(10ml: 0.42g)的药品生产注册批件,属于化学药品第3类,视同通过一致性评价。安瓿包装的碳酸氢钠注射液主要用于治疗代谢性酸中毒、硷化尿液及静脉滴注对某些药物的中毒。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10